Physician profile
Nancy Esper
NPI 1013006063
$10,511.75
in general payments reported to CMS, 2019-2025
52 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,595 · 2020: $1,086 · 2021: $1,587 · 2022: $1,085 · 2023: $2,143 · 2024: $1,648 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,979 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,978.99 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,856.96 | 2019-2025 | Evenity, Repatha, Repatha |
| Lilly USA, LLC | $944.26 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $922.15 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $695.53 | 2019-2025 | |
| Harmony Biosciences LLC | $670.97 | 2023-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $495.66 | 2019-2025 | |
| Pfizer INC. | $393.69 | 2019-2025 | |
| Esperion Therapeutics, INC. | $373.25 | 2021-2025 | Nexletol, Nexlizet |
| Amarin Pharma, INC. | $341.77 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $321.06 | 2022-2023 | Hetlioz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $296.76 | 2020-2025 | Xifaxan, Trulance |
| Allergan, INC. | $279.44 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $229.69 | 2019-2023 | Livalo, Seglentis |
| Idorsia Pharmaceuticals US INC | $228.95 | 2022-2025 | Quviviq, Quviviq |
| Inspire Medical Systems, INC. | $197.81 | 2023-2024 | Inspire |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $183.37 | 2023-2024 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Valeritas, INC. | $175.52 | 2019 | |
| Amneal Pharmaceuticals LLC | $146.42 | 2019-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $130.62 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $116.48 | 2019-2022 | |
| Corcept Therapeutics | $114.02 | 2025 | Korlym |
| Eli Lilly and Company | $92.53 | 2023 | |
| Astellas Pharma US INC | $90.52 | 2020-2025 | Veozah |
| Genentech USA, INC. | $73.90 | 2019-2021 | |
| Antares Pharma, INC. | $72.31 | 2021-2022 | |
| Agepha Pharma Fz LLC | $72.07 | 2024 | Lodoco |
| Merck Sharp & Dohme LLC | $71.95 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.85 | 2019-2021 | |
| Medicure Pharma INC. | $63.96 | 2019-2021 | |
| Ibsa Pharma INC. | $61.04 | 2020-2025 | Tirosint, Licart, Flector |
| Eisai INC. | $60.06 | 2021 | |
| Axsome Therapeutics, INC. | $52.27 | 2023-2024 | Sunosi |
| Dexcom, INC. | $49.03 | 2024-2025 | Dexcom G6 Transmitter |
| Arbor Pharmaceuticals, INC. | $48.55 | 2019-2021 | |
| Exact Sciences Corporation | $48.25 | 2023-2025 | Cologuard Collection Kit |
| Cleerly, INC. | $45.71 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Sumitomo Pharma America, INC. | $44.70 | 2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $44.48 | 2019 | |
| Paratek Pharmaceuticals, INC. | $39.67 | 2025 | Nuzyra, Xhance |
| Azurity Pharmaceuticals, INC. | $37.41 | 2024 | Horizant |
| Lucid Diagnostics INC. | $35.00 | 2025 | |
| Vivus LLC | $28.21 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.65 | 2025 | Ofev |
| Medtronic, INC. | $24.89 | 2023 | Venaseal |
| Tolmar, INC. | $23.94 | 2023 | |
| Shire North American Group INC | $23.62 | 2019 | |
| Tandem Diabetes Care, INC. | $21.12 | 2019 | |
| Amag Pharmaceuticals, INC. | $20.79 | 2019 | |
| Sanofi Pasteur INC. | $17.73 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.63 | 2019 | |
| Horizon Therapeutics Plc | $12.90 | 2019 | |
| Vistapharm, INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Esper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.